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Causative transcript: the transcript through which a genetic variant exerts its
effect on disease pathogenesis.
Common variant associations study (CVAS): a type of GWAS targeting
variants with a minor allele frequency (MAF) higher than 5%; Box 1 for details.
Expression quantitative trait loci (eQTL): a variant linked to the expression of a
specific gene. eQTLs that map near the affected transcript are referred to as cis-
eQTLs and those that are distal to the transcript are trans-eQTLs.
Exocrine pancreatic insufficiency: inadequate levels of digestive enzymes
secreted by the exocrine part of the pancreas.
Fine-mapping: the process of refining a disease-associated region by targeted
genotyping or sequencing in additional individuals, often from multiple ancestries.
Genetic variant: describes any type of variation at a given genomic position,
including single-nucleotide changes and structural variation (deletions and
insertions). Genetic variants can be classified based on whether they are
coding or non-coding (regulatory) and causative or incidental. Coding
mutations can be further divided into non-synonymous and synonymous
variations depending on the effect they have on the encoded amino acids. Both
non-synonymous mutations and structural variants can be protein-truncating if
the translated protein is shorter than the wild type.
Genome-wide association study (GWAS): broad term that encompasses both
CVASs and RVASs. Box 1 for details.
Haploinsufficiency: deviation from wild type state due to having only a single
functional copy of a given allele.
Mendelian diabetes: covers those forms of diabetes which show a Mendelian
pattern of inheritance (also sometimes referred to as monogenic diabetes). The
term includes both maturity onset diabetes of the young (MODY) and neonatal
diabetes mellitus (NDM), the two most common forms of Mendelian diabetes.
Minor allele frequency (MAF): frequency of the least common allele at a
particular locus.
Missing heritability: the gap between the heritability accounted for by currently
identified susceptibility variants and the variance in disease susceptibility
observed by population genetics.
Odds ratio (OR): used in GWASs as a measure of the effect size for a specific
variant. It is defined as the ratio between the proportion of cases and controls
carrying a genetic variant.
Penetrance: proportion of mutation carriers that express the expected
phenotype. A high penetrance is equivalent to a high OR. A highly penetrant,
disease-causing variant will be rare in the general population because of
reduced fitness. This trade-off between effect-size and frequency is exploited in
the search for low-frequency and rare T2D susceptibility variants which could
potentially have a higher OR.
Physiological characterisation: in the context of diabetes susceptibility,
physiological characterisation refers to the measurement of several quantita-
tive glycaemic traits. Frequently measured parameters include fasting
proinsulin (PI) levels, insulinogenic index (IGI), and various indices of glucose
tolerance. Such characterisation can provide insights into whether insulinDiabetesmellitus is ametabolic disease characterised by
relative or absolute pancreatic b cell dysfunction. Genet-
ic variants implicated in disease risk can be identified by
studying affected individuals. To understand the mech-
anisms driving genetic associations, variants must be
translated through causative transcripts to biological
insights. Studies into the genetic basis of Mendelian
forms of diabetes have successfully identified genes
involved in both b cell function and pancreatic develop-
ment. For type 2 diabetes (T2D), genome-wide associa-
tion studies (GWASs) are uncovering an ever-increasing
number of susceptibility variants that exert their effect
through b cell dysfunction, but translation to mechanis-
tic understanding has in most cases been slow. Im-
proved annotations of the islet genome and advances
in whole-genome and -exome sequencing (WHS and
WES) have facilitated recent progress.
Interrogating the genetic basis of diabetes
Over the past decades diabetes mellitus has been increas-
ing dramatically in prevalence and is predicted to affect
592 million worldwide by 2035 [1]. Auto-immune forms
currently make up 5–10% of all cases, and the remainder
predominantly comprises T2D. Changes in diet and life-
style are key drivers behind the T2D pandemic, but heri-
table factors are known to contribute to a significant
proportion of the phenotypic variance [2,3]. Studies into
the genetic susceptibility of T2D have supported the notion
that the disease develops due to an inability of the pancre-
atic b cell to compensate for increasing peripheral insulin
resistance [4,5]. The primary function of the b cell is in
metabolic homeostasis, achieved through a coupling of
ambient glucose levels with insulin secretion. In T2D
and related, rare forms of Mendelian diabetes, relative
or absolute b cell dysfunction leads to hyperglycaemia,
causing severe complications over time.
The study of human genetics provides a powerful tool to
understand the mechanisms underlying b cell dysfunction
in humans. Studies of individuals or populations with
diabetes can be used to identify genetic variants (see
Glossary) that either cause or increase susceptibility1043-2760/
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maturity onset diabetes of the young (MODY), referred
to collectively as Mendelian diabetes, the variants are rare
and highly penetrant. Regions containing such variationresistance or b cell dysfunction is driving particular associations.
Rare variant association study (RVAS): a type of GWAS targeting variants with
a MAF lower than 5% (low-frequency and rare variants); Box 1 for details.
Stretch enhancer: extended regulatory region bound by multiple transcription
factors and exhibiting tissue-specific enhancer activity. Stretch enhancers
mirror the related concepts of superenhancers, clusters of open regulatory
elements (COREs), and locus control regions.
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Box 2. Annotating the genome
Cataloguing transcription factor binding sites and epigenetic
features, such as histone modifications, can shed light on the func-
tion of regulatory genomic regions. Evidence for this has been
provided by recent studies in lymphoblastoid cell lines which have
demonstrated that non-coding SNPs, at least to some extent, exert
their cis-regulatory effects through disruption of transcription factor
binding (Figure 1B) [68–70]. The changes in occupancy in turn alter
the chromatin landscape both locally and at the promoter region of
nearby genes, thereby influencing transcriptional efficiency.
Chromatin states and transcription factor networks
To functionally annotate genomic features, microarray analysis or
WGS is applied to samples of DNA that are enriched or pretreated
in different ways. One of the most commonly used methods is
chromatin immunoprecipitation (ChIP) followed by microarray
analysis (ChIP-chip) or sequencing (ChIP-seq). ChIP makes use of
antibody-based purification to select genomic elements that are
associated with either specific transcription factors or modified
histones. Alternatively, isolation and identification of DNA fragments
not associated with proteins can identify regions of open chromatin
through so-called formaldehyde-assisted isolation of regulatory
elements (FAIRE). Further, to map out DNA methylation patterns,
approaches based on bisulfite conversion can be used to distinguish
unmethylated from methylated cytosines.
Variant-transcript regulatory links
A higher level of functional information is present in the relation-
ship between two distinct genomic elements. An important example
is the statistical correlation between a variant and the expression of a
particular gene. Such variants, so-called expression quantitative trait
loci (eQTLs), can be found by combining transcriptomic and genomic
datasets from islets, but require large sample sizes to obtain ade-
quate statistical power. Once identified, overlapping GWAS associa-
tion signals with cis-eQTLs (local eQTLs) can in principle provide
strong evidence in support of a specific causative transcript
(Figure 1). Large-scale studies are coming out, but early studies have
already demonstrated that particular expected cis-eQTLs can be
identified at a relaxed P value threshold [24]. Finally, variant-tran-
script links can also be identified by exploiting the fact that enhancers
tend to interact with the promoter regions of target genes. By
chromatin-conformation capture (3C)-based approaches it is possi-
ble to identify genomic elements that are in close spatial proximity
owing to folding and looping of chromatin.
Box 1. Identifying genomic regions implicated in diabetes
risk
Linkage analysis and positional cloning
For highly penetrant mutations causing Mendelian diabetes,
positional cloning has been an invaluable tool to identify genes
implicated in disease pathogenesis. The principle is based on the
tendency of genetic elements in close proximity to be coinherited.
By mapping disease-causing variants relative to cosegregating
genetic markers (DNA sequences of known position that show
variation in sequence or length between individuals) the approx-
imate position in the genome can be established. Typically, this
approach will identify a candidate gene region covering millions of
basepairs. Following this, several overlapping clones covering the
region can be generated and the causative gene identified.
GWAS, RVAS, and CVAS studies
For complex forms of diabetes, numerous genes with small effect
sizes and low penetrance contribute to disease susceptibility. Thus,
rather than using linkage-based approaches, GWASs are applied to
large samples of individuals with and without diabetes to establish
statistical evidence for association of particular variants with the
disease. The ratio between the frequency of an allele in cases
compared with controls is referred to as the odds ratio (OR), a
measure of the effect size of a variant. An OR of 1 indicates no effect,
whereas an OR significantly different from 1 shows evidence of
either a protective (OR <1) or harmful effect (OR >1). GWASs that
target common SNPs [minor allele frequency (MAF) >5%)] using
microarray technology are referred to in this review as common
variant association studies (CVASs). By contrast, studies that target
low-frequency (0.5%>MAF> 5%) and rare variants (MAF< 0.5%) by
either sequencing-based approaches or microarrays designed to
capture such SNPs are referred to as rare variant association studies
(RVASs). Although often simply called exome-sequencing studies,
we refrain from using this terminology to avoid mixing up statistical
and genotyping methodologies [6].
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positional cloning (Box 1), but technological advances have
recently resulted in WES and WGS becoming more com-
mon. For T2D, which is a multifactorial disease, the sus-
ceptibility variants have smaller effect sizes and can
become more common due to reduced purifying selection.
The majority of variants established to date have been
identified through common variant association studies
(CVASs), a type of GWAS targeting common variants
(Box 1) [6]. The associations, however, have been found
insufficient to account for measures of T2D heritability.
To address this, rare variant association studies (RVASs)
have been increasingly used to capture lower-frequency
variants of moderate effect sizes (Box 1). The findings from
studies on the genetics of bothMendelianand complex types
of diabetes provide biological insights that have the poten-
tial to be translated directly into clinically relevant disease
mechanisms. This advantage to human genetics is particu-
larly evident in cases where rodent models have been found
to inadequately recapitulate human phenotypes [7–9].
Despite advances in identifying genetic variants that
increase diabetes susceptibility, the translation of associa-
tion signals into molecular mechanisms has in many cases
been slow. Exceptions include regions where biologically
relevant genes harbour coding variants [10]. Many signals,
however, are located in intergenic regions, and assigning a
causative transcript to a particular variant presents a
significant challenge (Figure 1A). Recent progress in struc-
turally and functionally annotating the islet genome has
provided a context in which to understand the effects of426non-coding variants, and has in some cases facilitated
translation into biological mechanisms (Figure 1B)
[11–14].
In this review we first describe the current state of
genomic annotation in islets, focusing on the biological
impact of this work. Second, we discuss new insights intob
cell biology from variants causing or increasing suscepti-
bility to T2D and related forms of Mendelian diabetes.
Where relevant we highlight the use of islet genome
annotation to interrogate variation, a strategy that will
become increasingly important in understanding how
non-coding variants impact on the molecular machinery
of the b cell.
Understanding the impact of regulatory variants on islet
gene function
Genomic annotation is the process of assigning structural
and functional meaning, such as gene structure and chro-
matin modifications, to specific sequences in the genome
(Box 2). Many of these features are dynamically regulated,
and therefore vary according to developmental stage, met-
abolic state, or tissue type. The ENCODE project hasmade
significant progress in cataloguing genomic features
(including various histone modifications and transcription
[(Figure_1)TD$FIG]
Figure 1. The mechanisms underlying disease-associated genetic variants. (A) Location of a non-coding and a coding genetic variant relative to three genes: A, B, and C.
The coding variant is likely to exert its influence on disease pathogenesis through an effect on the function of gene C. Several different mechanisms, including amino acid
substitution and protein truncation, could be driving the association. The non-coding variant, on the contrary, could be acting through any of the three nearby genes, as
shown by the dotted arrows indicating potential cis-regulatory links. The variant could, for example, affect either expression levels or splicing patterns, but identifying the
causative transcript can be challenging. (B) The schematic depicted in panel A with additional functional annotations (Box 2 for details). The binding sites of three b cell
specific transcription factors (TF 1, 2 and 3) are shown by lines connected to the respective proteins. Three binding sites cluster to form a stretch enhancer, which is likely to
have islet-specific cis-regulatory activity (see the section ‘Understanding the impact of regulatory variants on islet gene function’). The non-coding variant is seen to overlap
with the binding site of TF2 within the stretch enhancer, and could therefore plausibly act through disruption of TF2 binding. The solid arrow shows an established cis-
regulatory link between the variant and gene 1. This relationship could be supported by different types of functional annotation, including a correlation between the non-
coding variant and expression of gene 1 (established by cis-eQTL studies) or a physical interaction between the enhancer and the promoter region of gene 1 (demonstrated
by chromatin-conformation capture, 3C) (Box 2). With such annotations at hand, identifying the causative transcript at a disease-associated locus is a more tractable
problem.
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does not currently include either pancreatic islets or b
cells. To obtain information that is directly relevant to
our understanding of those diabetes risk variants that
exert their effect through b cell dysfunction, several groups
have recently addressed this issue. In most of these stud-
ies, islets of Langerhans have been used as a proxy for b
cells, which make up 65–80% of the human islets but are
hard to isolate as a pure fraction. Some have focused on
identifying transcription factor binding sites or regions
with specific states of chromatin [13–19].
Other studies have performed transcriptomic analyses
to provide a wealth of information on the expression of both
protein-coding genes and non-coding RNAs, thereby
expanding the classes of structural elements that can be
interrogated when considering the impact of genetic var-
iants [20–23]. Such datasets have also been integrated
with genomic data to enable genome-wide testing for var-
iants that affect transcript levels, so-called expression
quantitative trait loci (eQTL) (Box 2) [23,24]. Early studies
have been limited by insufficient statistical power owing to
relatively small sample sizes, but large-scale eQTL efforts
in islets are currently underway and are anticipated toprovide an important layer of regulatory information to the
islet genome.
One of the key lessons emerging from the genomic
annotations has been an increased understanding of how
islet-specific genes are regulated. Several studies have
made observations which indicate that genes involved in
b cell identity and function tend to be regulated by clusters
of transcription factors rather than by orphan enhancers
[13,14,17]. The clusters form stretch- or super-enhancers
that may act as molecular runways for tissue-specific
transcription factors [17,25,26] (Figure 1B). Importantly,
the islet stretch enhancers are found to be enriched for
variants associated with susceptibility to diabetes and
related metabolic traits [13,17].
From association signal to molecular mechanism
Mendelian diabetes
Mendelian forms of diabetes encompass a group of dis-
eases, including both MODY and NDM, which show a
Mendelian pattern of inheritance. Because of the clear
genotype–phenotype correlation they constitute an invalu-
able tool for understanding how the disruption of a partic-
ular gene can impact on molecular and physiological427
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lian diabetes have been remarkably successful in identify-
ing genes implicated in pathogenesis, including both
components of the insulin secretory pathways (e.g.,
ABCC8, GCK, INS, KCNJ11) (Figure 2A) and developmen-
tally important transcription factors (e.g., HNF1A,
HNF4A, PDX1, PTF1A) [27]. In some instances the
insights arising from these studies have enabled substan-
tial therapeutic advances, most notably in the case of
sulfonylurea treatment for patients with mutations in
genes encoding subunits of the KATP channel (ABCC8
and KCNJ11) [28].
The genetics of Mendelian diabetes is continuing to
provide insights intob cell function, facilitated by advances
in sequencing-based approaches, such as WES and WGS,
and in genomic annotation. WES offers the possibility to
discover coding, disease-causing mutations in an untar-
geted manner, as recently demonstrated by a study inves-
tigating the genetic aetiology of pancreatic agenesis
[8]. This rare condition, which clinically manifests itself
through both diabetes and exocrine pancreatic insufficien-
cy, is caused by complete or partial failure of the pancreas
to develop. Lango Allen and colleagues performed WES on
a subset of probands from a cohort of individuals with
unexplained pancreatic agenesis. The authors used a com-
mon strategy of filtering against synonymous and known
variation to enrich for likely pathogenic variants, and this
identified heterozygous de novo mutations in the GATA6
(GATA-binding factor 6) gene. Targeted sequencing of
GATA6 in further subjects revealed additional non-synon-
ymousmutations in over half the individuals. Mutations in
GATA6 have subsequently been shown in follow-up studies
to cause a spectrum of diabetic phenotypes, ranging from
pancreatic agenesis to adult-onset diabetes with no overt
exocrine insufficiency [29,30]. This incomplete penetrance
of GATA6-inactivating mutations has also been noted by
Bonnefond et al., who showed that cardiac malformation is
a more consistent phenotype of mutation carriers [31]. The
variability in clinical presentation presumably reflects
both mutational burden as well as genetic background.
Overall, these studies have established that GATA6 hap-
loinsuffiency is a major cause of syndromic pancreatic
agenesis and point to a crucial role for GATA6 in pancreatic
development. Furthermore, this discovery highlights the
value of using human genetics to understand gene-dosage
relationships for dominant variants because heterozygous
Gata6 knockout mice show no apparent phenotype [8].
Unlike exome-based approaches, WGS can be used to
identify both coding and regulatory variants. In non-coding
regions, however, predicted disruption of protein function
cannot be used as an indicator of pathogenicity. A chal-
lenge for WGS-based studies into Mendelian diseases is
therefore related to the filtering of incidental variation
from disease-causing mutations, and particularly in cases
where linkage information is limited. A study into the
genetic basis of patients with non-syndromic pancreatic
agenesis (no extra-pancreatic features) explored the poten-
tial in combining WGS with spatially and temporally
relevant genomic annotations to identify a subset of func-
tionally active regulatory variants [11]. The study focused
on homozygous mutations, consistent with the observation428that close to half of the studied individuals were to born to
consanguineous parents [8,11]. Failing to identify any
plausible coding variants, the authors extended their
search to developmentally active enhancer regions. Such
an annotated map was obtained by defining enhancers
bound by multiple transcription factors in pancreatic en-
doderm derived from human embryonic stem cells. In this
way, a putative stretch enhancer downstream of PTF1A
(pancreas transcription factor 1) was found to contain
homozygous mutations in 9 of 12 individuals with isolated
pancreatic agenesis. Compelling genetic and functional
evidence established the pathogenicity of the variants,
which all seem to abolish enhancer activity through dis-
ruption of transcription factor binding. Recessive coding
mutations in PTF1A have previously been implicated in
Mendelian diabetes, but are in all these cases associated
with neurological features [32,33]. Interestingly, the distal
enhancer found to harbour mutations causing isolated
pancreatic agenesis does not have active marks in any
ENCODE-annotated tissue type, suggesting that tissue-
specific regulation can account for the absence of extra-
pancreatic features [11].
The observation that some mouse models (e.g., GATA6,
HNF1A) show poor phenotypic correlation with humans
questions the degree to which mice can provide relevant
insights into human pancreatic development [7,8,34]. To
address this issue more systematically, Flanagan et al.
screened for homozygous mutations in individuals with
NDM born to consanguineous parents [9]. The study fo-
cused on 29 genes known to be important regulators of
mouse pancreatic development. In total, seven of the genes
were found to be affected in the studied collection, includ-
ing NKX2-2 (NK2 homeobox protein 2) andMNX-1 (motor
neuron and pancreas homeobox 1), which had not previ-
ously been associated with NDM. Comparison between the
clinical features of the subjects (both pancreatic and extra-
pancreatic) and the corresponding phenotypes of homozy-
gous-null mouse models revealed pronounced similarities
across all seven genes. Thus, it seems that the phenotypic
correlation between humans and mouse models is gener-
ally high for biallelic inactivations.
Overall, the genetics of rare Mendelian forms of diabe-
tes have provided a wealth of information into both the
function of b cells and more recently also pancreatic devel-
opment (Figure 2). The insights generated by these and
other studies enhance our understanding of the transcrip-
tional networks that regulate human pancreatic develop-
ment [35,36]. Integration of genetics and functional
genomics has been established as a powerful tool to inter-
rogate regulatory variation, but the proportion of non-
coding variants causing Mendelian diseases is still uncer-
tain [6].
Type 2 diabetes
In contrast to Mendelian forms of diabetes, the genetic
contribution to T2D is obscured by environmental influ-
ences and the relatively low penetrance of susceptibility
variants. As a consequence, genetic variants are identified
through association studies by establishing statistical evi-
dence for overrepresentation in cases compared with con-
trols (Box 1). Once identified at a stringent genome-wide
[(Figure_2)TD$FIG]
Figure 2. Schematic representation of the pancreatic b cell and the location of key components implicated by human genetics in diabetes pathogenesis. Solid arrows
indicate direct mechanisms of action and dotted arrows indicate mechanisms with intermediate events not displayed in the schematic. (A) Consensus model of glucose-
stimulated insulin secretion (GSIS), including several key proteins involved in Mendelian forms of diabetes. Proteins depicted: GCK (encoded by GCK), GLUT1/2/3 (SLC2A1/
2/3), insulin (INS), Kir6.2 (KCNJ11), SUR1 (ABCC8), and voltage-gated Ca2+ channels (CaVs), which represent both P/Q type and L-type channels ([71] for details). Briefly,
glucose enters the cell through one of the glucose transporters GLUT1/2/3 and is phosphorylated by GCK to form glucose-6-phosphate (G6P). In the mitochondria, aerobic
metabolism of glycolytic products results in the generation of ATP. Changes in the ATP:ADP ratio inactivates the ATP-sensitive potassium channel KATP, which consists of
four SUR1 and four Kir6.2 subunits. Closure of KATP in turn causes depolarization of the membrane opening voltage-gated Ca
2+ channels. Finally, the influx of Ca2+ triggers
exocytosis of insulin granules. (B) Location and proposed role in b cell function of proteins encoded by genes discussed in this review. Proteins depicted: ANKRD15
(encoded by KANK1), CDK4/6 (CDK4 and CDK6), cyclin D2 (CCND2), KvLQT1 (KCNQ1), Mel-1B (MTNR1B), PAM (PAM), TBC1D30 (TBC1D30), ZnT-8 (SLC30A8), and the
transcription factors GATA-6 (GATA6), MNX1 (MNX1), Nkx-2.2 (NKX2-2), PDX-1 (PDX1), PTF1-p48 (PTF1A), and TCF4 (TCF7L2). See main text for details of individual genes.
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Figure 3. From association signal, through causative transcript, to biology. Beige boxes contain key experimental procedures; blue boxes indicate the entity of focus along
the process of translating genetic associations to biology; and red boxes are divisions of such entities. As summarised in Box 1, human genetics can identify genomic
regions implicated in diabetes risk. Subsequently, fine-mapping approaches can refine the genetic associations and identify the causative variant. Physiological
characterisation of individuals carrying those risk alleles can in turn reveal effects indicative of the tissue(s) affected, but only indirect evidence for the underlying
mechanisms (dotted line). Instead, identifying the transcripts driving the association of b cell relevant variants provides more direct insight into disease biology. For coding
variants this can be achieved by prediction or validation of pathogenicity, whereas for non-coding signals consideration of prior candidate gene biology for nearby genes or
variant transcript links can prioritize regional transcripts. Once a causative transcript has been identified, several different approaches, including human models, animal
models, and functional studies, can be used to interrogate the function of the protein and ascertain its role in disease biology. Abbreviations: 3C, chromatin conformation
capture; cis-eQTL, cis-expression quantitative trait loci (Box 2).
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tive transcripts, which can be interrogated for biological
function (Figure 3). A few of the 77 susceptibility regions
previously found to be associated with T2D contain a non-
synonymous variant in the coding region of a gene
[4,5,37]. In such cases (e.g., KCNJ11, SLC30A8, and
GCKR), identifying the causative transcript is relatively
straightforward and can be immediately followed up with
functional studies and animal models [10]. For the remain-
ing loci, however, the variants reside in non-coding regions
of the genome, making it a challenge to establish a causal
link between the signal and a nearby gene (Figure 1). We
discuss here progress concerning variants from across the
frequency spectrum.
Common variants
Most of the established T2D-associated loci are common
variants that have been identified through CVASs
[4,5,37]. Physiological characterisations of carriers have
demonstrated that, although T2D is etiologically hetero-
geneous, themajority of these association signals appear to
act through b cell dysfunction [4,38,39]. Thus, inferring the
causative transcripts from risk variants holds the promise
to identify genes that are important for b cell function.
In the case of the TCF7L2 (transcription factor 7-like 2,
T cell specific, HMG-box) locus, improvements in islet
genomic annotations have provided new insights into
the mechanism of an intronic risk variant [13,14]. The
association signal has been the focus of particular interest430because of its relatively large effect size [odds ratio
(OR) = 1.4 in the CEU (Central European) cohort], the
highest of any common variant in Caucasian populations
[5]. Despite the high OR, functional studies have shown
inconsistent effects ofTCF7L2 levels on b cell function, and
the primary tissues through which the effect is expressed
has remained controversial [40–44]. Genomic annotations,
however, have provided several lines of evidence support-
ing islet-specific enhancer activity. First, Gaulton et al.
were able to show that the TCF7L2 association signal is
located in an islet-selective region of open chromatin,
indicative of regulatory activity [14]. The risk allele is itself
associated with a more accessible state of chromatin and
increased enhancer activity in b cell lines [14,18]. Further,
it has been demonstrated by a comprehensive analysis of
transcription factor binding sites in islets that the region
containing the lead single-nucleotide polymorphism (SNP)
is a stretch enhancer, bound by three key islet transcrip-
tion factors [13]. Together, these observations provide
strong evidence in favour of a b cell driven effect on T2D
susceptibility (Figure 2B).
A different type of regulatory relationship has been
described for the intronic variants at the KCNQ1 (potassi-
um voltage-gated channel, KQT-like subfamily, member 1)
locus. The region contains both multiple independent as-
sociation signals and biologically plausible transcripts,
including KCNQ1 (Figure 2B). Consistent with the
imprinted status of the locus, it is one of only two T2D
loci to display a strong parent-of-origin effect [45,46].
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functionmutations inKCNQ1 has demonstrated increased
insulin secretion, highlighting KCNQ1 as a likely causa-
tive transcript [47]. This is reinforced by a study investi-
gating the imprinting status of regional transcripts in
foetal and adult islets [12]. Evidence of monoallelic expres-
sion was observed for KCNQ1 in the foetal but not in the
adult state, arguing that any potential effect on T2D must
be developmental. Thus, KCNQ1 is emerging as a strong
candidate at the locus, although the possibility of effects on
other regional transcripts, such asCDKN1C (cyclin-depen-
dent kinase inhibitor 1C; encoding p27KIP2), cannot be
excluded [19].
Low-frequency and rare variants
Despite the large number of common variants having been
discovered by CVASs, the combined population-attribut-
able risk accounts for only a small fraction of the total
heritability of T2D (Box 3) [4,5]. This has prompted spec-
ulations that rare and low-frequency variants of moderate
effect sizes could explain a significant proportion of the
‘missing heritability’ [48]. Early RVASs have addressed
this conundrumdirectly by targeting either specific regions
already established by CVAS, or by examining the whole
exome or genome in an unbiased fashion [49–52].
An initial study of this kind focused onMTNR1B (mela-
tonin receptor 1B), a genepreviously implicated in bothT2D
and fasting glucose levels by CVASs [53,54]. The melatonin
receptor 1B is an inhibitory G protein-coupled receptor
(GPCR) that modulates insulin secretion (Figure 2B). It
has attracted attention both because of the therapeutic
value of GPCRs but also because of the potential link
between circadian rhythm and metabolic control; releaseBox 3. Missing heritability in T2D
Common variants identified to date together account for less than
10% of the variance in diabetes susceptibility estimated by twin and
segregation studies [5,48]. To account for this ‘missing heritability’
several potential sources have been proposed, including gene–en-
vironment interactions, structural variants not captured by existing
GWASs, rare variants of moderately high effect size, incorrect esti-
mates of heritability, and inappropriate study design. Rare variants in
particular have attracted attention recently and the focuses of many
GWASs have shifted from CVAS towards RVAS. The notion of rare
variants contributing to disease susceptibility is supported by rese-
quencing of the diabetes susceptibility genes KCNJ11 and HHEX,
which revealed an unexpectedly large number of rare variants arising
because of recent explosive population growth [72]. Conversely,
modelling of the distribution of common variants has shown that
a very large number of such variants may be associated with T2D
[5]. These would explain a majority of the heritability but require
unfeasibly large populations for genome-wide significance owing to
progressively smaller effect sizes. Supporting this, Lohmueller and
colleagues combined simulations with sequencing of a limited num-
ber of individuals, and concluded that their observations were in-
consistent with a model where rare variants in a modest number of
genes explain the majority of diabetes susceptibility [73]. However,
recent studies with larger samples sizes have been able to establish
exome-wide levels of statistical significance for rare variants at both
new and previously established T2D loci (main text for details). As for
common variants, it appears that the limited number of rare variants
identified so far primarily affect b cell function. Overall, despite their
relatively high ORs, the population-attributable risks remain low
because of their low frequencies, and it remains to be seen whether
rare variants contribute significantly to T2D heritability.of melatonin from the pineal gland is inhibited by light, and
thus the endocrine hormone is thought to reduce insulin
secretion during the night. Because MTNR1B expression
was initially observed to be higher in individuals with T2D
than in controls it was expected that the common risk
variant would increase expression [54]. This, in turn, would
lead to inappropriately high inhibition of insulin secretion
by melatonin. Resequencing of the region, however, identi-
fied several rare variants that caused pronounced decreases
in receptor function [49]. The variantswere too rare to allow
association tests at the level of individual variants but were
aggregated to increase statistical power, a common practice
in RVASs [6]. Grouping based on functional effect estab-
lished that alleles harbouring rare loss-of-function variants
significantly increases susceptibility to T2D (OR = 5.7). By
contrast, ameta-allele consisting of all rare variants showsa
diluted effect (OR = 3.3). This demonstrates the importance
of correctly assigning pathogenicity to exclude incidental
mutations and thereby increase power. In addition to dis-
covering an unexpected direction of effect, the study also
provides proof-of-principle that rare variants with large
effect sizes can be found by resequencing loci prioritized
by CVAS.
Targeted resequencing has also been remarkably suc-
cessful in shedding light on the direction of effect at the
SLC30A8 (solute carrier family 30 member 8) locus [50].
SLC30A8 encodes a Zn2+ transporter, ZnT-8, that localises
to the insulin-containing secretory granules (Figure 2B). It
was first proposed that a common non-synonymous variant
identified by CVAS would decrease function of the trans-
porter, leading to an insulin crystallization defect. Never-
theless, follow-up functional studies and animal models
have only reported small, incongruent effects on b cell
function [55–59] (reviewed in [60]). To resolve this, Flan-
nick et al. genotyped 150 000 individuals looking for T2D-
association of rare variants with large functional effects
[50]. By aggregating all protein-truncatingmutations, they
were able to show at an exome-wide level of significance
that loss-of-function variants are protective against T2D
(OR = 0.34). Demonstrating the power of human genetics
to determine mechanistic directionality, this surprising
finding shows that a 50% reduction of ZnT-8 levels
decreases the risk of developing T2D by almost threefold.
To understand the underlying protective mechanism and
evaluate the potential of ZnT-8 as a therapeutic target,
these new insights will need to be reconciled with existing
data, as discussed elsewhere [60].
Two RVASs so far have attempted to uncover new loci by
non-targeted approaches [51,52]. Huyghe et al. provided
proof-of-principle using an exome-chip approach to investi-
gate several T2D-relevant traits in healthy adults [51]. The
study identified associations for insulinogenic index (IGI), a
measure of insulin release in response to glucose, and
proinsulin (PI) levels, a proxy for b cell stress. The three
genes found to be implicated are all strong biological candi-
dates: PAM (peptidylglycine a-amidating monooxygenase;
associated with IGI) encodes an a-amidase localising to the
membrane of secretory granules, and both KANK1 (KN
motif and ankyrin repeat domains 1) and TBC1D30
(TBC1domain family,member 3; associatedwithPI) encode
proteins involved in G-protein signalling (Figure 2B).431
Box 4. Outstanding questions
 How is the balance between secretion, proliferation, and apopto-
sis ultimately regulated and disturbed by T2D susceptibility var-
iants that exert their effect through b cells? Translating more
variants to biological mechanisms will improve our understand-
ing of this complex system and thereby also diabetes pathogen-
esis (Figure 3).
 Will larger cis-eQTL studies and other functional annotations, such
as chromatin conformation capture (3C) (Box 2), deliver the antici-
pated advance in facilitating translation of regulatory variants to
molecular mechanisms?
 Will rare variants contribute significantly to themissing heritability
of T2D? In addition, will rare variants, similarly to common var-
iants, primarily exert their effect on diabetes susceptibility through
b cell dysfunction?
 What proportion of rare variantswill be found in regulatory regions
of the genome? There is reason to believe that rare variants with
moderate and high effects are less likely to be regulatory than
common variants because of the more dramatic effect that coding
mutations can have on protein function.
Review Trends in Endocrinology and Metabolism August 2014, Vol. 25, No. 8More recently, the deCODE consortium has studied a
cohort of Icelanders to test for associations of rare and low-
frequency variants with T2D [52]. By combining WGS of a
limited number of individuals with imputation based on
Icelandic genealogy they were able to obtain an effective
sample size of close to 300 000 individuals. This provided
sufficient power to establish four previously unreported
association signals in three regions: PAM, in which a rare
variant had also previously been associated with IGI (see
above), CCND2 (cyclin D2), and PDX1 (pancreatic and
duodenal homeobox 1) (Figure 2B). Interestingly, the intro-
nic variant in CCND2 was protective against T2D
(OR = 0.5) but was associated with higher body mass index
(BMI) and height. Cyclin D2 is a widely expressed regula-
tor of the G1/S cell cycle transition and has been shown to
influence the proliferative capacity of b cells among many
other cell types [61]. PDX1 encodes a transcription factor
important for b cell maturation and is known to be involved
in Mendelian forms of diabetes [27]. Accordingly, a rare
frameshift mutation was shown to have a moderately high
effect (OR = 2.3) [52].
The discovery of PDX1 as a T2D risk locus expands the
overlap between genes implicated in T2D susceptibility
and genes known to be involved in Mendelian diabetes
(e.g., KCNJ11, HNF1A, HNF1B, WFS1). Blurring the
boundary between the two diseases, it has recently been
shown that the apparent deterministic effect of particular
MODY-mutations may reflect an inflated estimate of effect
size as a result of ascertainment bias [62]. As more rare
variants with large effect sizes become associated with
T2D, the operational cut-off point for classification of a
mutation as an incompletely penetrant Mendelian variant
or a rare T2D mutation with a high effect size will become
increasingly arbitrary.
Concluding remarks and future perspectives
Human genetics has proven a powerful instrument to ex-
plore the genetics ofb cell dysfunction. Substantial progress
has been made from studies into Mendelian forms of diabe-
tes,whichhave improvedourunderstanding ofb cell biology
and delivered validated drug targets. Translation of initial
T2D variants has been slower, but recent studies have
shown progress in elucidating the mechanisms underlying
several common and low-frequency susceptibility variants
(Figure 2) [37,51,52]. Several large-scale sequencing efforts
by international consortia are currently underway, and
these will undoubtedly further expand the number of ro-
bustly associated genetic variants. Although it seems un-
likely that the first generation of such studies will uncover a
large proportion of the missing heritability, they may shed
much needed light on the overall distribution of variant
frequencies and effect sizes at T2D loci.
One of the greatest challenges in the field remains to
bridge the gap between regulatory variants and causative
transcripts, but several new methods are promising to
accelerate this process. First, the identification of rare,
coding variants in regions associated with common regu-
latory variants can provide prior evidence in favour of
particular transcripts. Proof-of-principle RVASs have al-
ready been published, but studies with larger sample sizes
will provide greater statistical power [51,52]. A second432approach is based on annotation of the islet genome
through the integration of large-scale genomics and tran-
scriptomics datasets. Understanding the genomic context
of genetic associations enables the identification of a func-
tionally active subset of variants and even prediction or
direct determination of the impact that specific alleles have
on chromatin states. A large number of studies have
already contributed to annotating the islet genome, creat-
ing an atlas with a growing number of structural and
functional layers. As an extension of this principle, cis-
eQTL studies promise to deliver an additional level of
information by identifying correlations between genotypes
and expression levels.
Once a causative gene has been inferred, the discovery
must be followed up by studies to interrogate the biological
function of the encoded gene product. Only then can we
gain new insights into b cell biology and appreciate the full
implications for disease pathogenesis. For such follow-up
studies, traditional characterisation of animal models is
being increasingly supplemented by new human model
systems. The generation of the first glucose-responsive
human b cell line was recently reported [63]. Although
still an imperfect model, the cell line represents a major
step forward and will complement current work in rodent
cell lines. In addition, advances are being made in both the
derivation of induced pluripotent stem (iPS) cells and in
their subsequent differentiation to the endodermal lineage
[64–66]. Soon patient-derived iPS cells will be used rou-
tinely to study b cell function. Novel genome-editing tools
such as the CRISPR/cas system are already available for
fast and simple genetic manipulation of cell lines and iPS
cells [67]. In this way it is possible to create both knockouts
andmodels carrying risk alleles withmore subtle effects on
splicing or function. Finally, appropriate physiological
characterisation of human variant-carriers will provide
increasingly detailed insight into pathophysiologicalmech-
anisms.
Future studies evaluating genetic associations will be
supported by such new methods, and thereby accelerate
the process of going from variant through transcript to
biology. The insights arising from human genetics will
continue to improve our understanding of b cell function
Review Trends in Endocrinology and Metabolism August 2014, Vol. 25, No. 8(Box 4), inspiring the development of novel drugs and
facilitating advances in replacement therapies.
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